Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Cited In for PubMed (Select 14576047)

1.

Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.

Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):292-7. doi: 10.1016/j.clml.2014.11.001. Epub 2014 Nov 15.

2.

Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia.

Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z.

Br J Haematol. 2015 May;169(4):595-7. doi: 10.1111/bjh.13230. Epub 2014 Nov 21. No abstract available.

PMID:
25413673
4.

High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure.

Smith MB, Griffiths EA, Thompson JE, Wang ES, Wetzler M, Freyer CW.

Leuk Res Rep. 2014 Jul 30;3(2):62-6. doi: 10.1016/j.lrr.2014.07.001. eCollection 2014.

5.

Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome.

Cardinale L, Asteggiano F, Moretti F, Torre F, Ulisciani S, Fava C, Rege-Cambrin G.

World J Radiol. 2014 Aug 28;6(8):583-8. doi: 10.4329/wjr.v6.i8.583. Review.

6.

Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.

Gómez-Seguí I, Sánchez-Izquierdo D, Barragán E, Such E, Luna I, López-Pavía M, Ibáñez M, Villamón E, Alonso C, Martín I, Llop M, Dolz S, Fuster O, Montesinos P, Cañigral C, Boluda B, Salazar C, Cervera J, Sanz MA.

PLoS One. 2014 Jun 24;9(6):e100245. doi: 10.1371/journal.pone.0100245. eCollection 2014.

7.

Contemporary treatment of APL.

Cull EH, Altman JK.

Curr Hematol Malig Rep. 2014 Jun;9(2):193-201. doi: 10.1007/s11899-014-0205-6. Review.

8.

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Br J Haematol. 2014 May;165(4):497-503. doi: 10.1111/bjh.12775. Epub 2014 Feb 14.

9.

Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia.

Albano F, Zagaria A, Anelli L, Orsini P, Minervini CF, Impera L, Casieri P, Coccaro N, Tota G, Brunetti C, Minervini A, Pastore D, Carluccio P, Mestice A, Cellamare A, Specchia G.

Oncotarget. 2014 Feb 15;5(3):649-58.

10.

Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.

Dos Santos GA, Kats L, Pandolfi PP.

J Exp Med. 2013 Dec 16;210(13):2793-802. doi: 10.1084/jem.20131121. Review.

11.

Update on optimal management of acute myeloid leukemia.

El Rassi F, Arellano M.

Clin Med Insights Oncol. 2013 Aug 12;7:181-97. doi: 10.4137/CMO.S8528. eCollection 2013.

12.

Management of elderly patients with acute promyelocytic leukemia: progress and problems.

Lengfelder E, Hofmann WK, Nolte F.

Ann Hematol. 2013 Sep;92(9):1181-8. doi: 10.1007/s00277-013-1788-z. Epub 2013 May 22. Review.

13.

FISH detection of PML-RARA fusion in ins(15;17) acute promyelocytic leukaemia depends on probe size.

Campbell LJ, Oei P, Brookwell R, Shortt J, Eaddy N, Ng A, Chew E, Browett P.

Biomed Res Int. 2013;2013:164501. doi: 10.1155/2013/164501. Epub 2013 Mar 28.

14.

Emerging new approaches for the treatment of acute promyelocytic leukemia.

Park J, Jurcic JG, Rosenblat T, Tallman MS.

Ther Adv Hematol. 2011 Oct;2(5):335-52. doi: 10.1177/2040620711410773.

15.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Ann Hematol. 2013 Jan;92(1):41-52. doi: 10.1007/s00277-012-1597-9. Epub 2012 Oct 23.

16.

Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W.

Blood. 2012 Sep 6;120(10):2098-108. doi: 10.1182/blood-2012-01-407601. Epub 2012 Jun 25.

17.

Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF).

Ayala R, Martínez-López J, Gilsanz F.

Cancer Cell Int. 2012 Jun 7;12(1):25. doi: 10.1186/1475-2867-12-25.

18.

Therapeutic targeting of cancer stem cells.

Maugeri-Saccà M, Zeuner A, De Maria R.

Front Oncol. 2011 Jun 17;1:10. doi: 10.3389/fonc.2011.00010. eCollection 2011.

19.

Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Falanga A, Russo L, Tartari CJ.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011068. doi: 10.4084/MJHID.2011.068. Epub 2011 Dec 21.

20.

Clinical features and treatment outcome of acute promyelocytic leukemia patients treated at cairo national cancer institute in egypt.

Khorshid O, Diaa A, Moaty MA, Fatah RA, Dessouki IE, Hamid MA, Noshokaty EE, Saied GE, Fouad TM, Ramadan SM.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011060. doi: 10.4084/MJHID.2011.060. Epub 2011 Dec 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk